Tuesday November 18, 10:00 am ET
Press Release Source: BioReliance Corporation
ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that it has concluded an agreement with Provecs Medical GmbH, a company based in Hamburg, Germany, for production of investigational quantities of Immunalon®, a novel therapeutic agent based upon an adenovirus vector that stimulates an immunological response against tumor cells.
Dr. Frank Schnieders, the Chief Executive Officer of Provecs and one of its founders, commented on the agreement, stating, “With the conclusion of this agreement with BioReliance, we have moved significantly closer to the commencement of clinical trials with Immunalon®. In animal studies, it has been shown capable of stimulating a strong immunological response to tumor cells. It holds the possibility of causing the immune system to attack and destroy tumors and their metastases. We selected BioReliance to manufacture investigational quantities of Immunalon® because of their reputation for quality and reliability.”
BioReliance Account Manager, Dr. Florian Schwaak, who concluded the agreement with Provecs, stated, “On behalf of the BioReliance team, I would like to thank Dr. Schnieders for allowing us to play a role in the development of Immunalon®. It represents an exciting new direction in cancer therapies.”
About BioReliance
BioReliance is a leading specialist provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing, GMP manufacturing, pre-clinical testing and lab animal health diagnostics. Founded in 1947 as Microbiological Associates, BioReliance is headquartered in Rockville, Maryland, and has primary facilities in Rockville, Glasgow, Scotland, and Stirling, Scotland, employing more than 700 people globally. For more information, visit www.bioreliance.com.
Contact:
BioReliance Corporation
Martin Wisher, PhD, Scientific Director
+44(0) 1786 273019
martin.wisher@bioreliance.com
or
Philip A. Theodore, Vice President – Compliance
Legal and Corporate Development
301-610-2674
phil.theodore@bioreliance.com
Source: BioReliance Corporation